SCF ENCYCLOPEDIA ENTRY

NEW-ONSET TYPE 2 DIABETES POSTPARTUM

SCF-RDOS Registry Code: SCF-RDOS-PPD-END-007

Disease Type Classification: Endocrine Disease → Diabetes Mellitus → Postpartum Type 2 Diabetes Syndrome

Adaptive Module Activation:

• Universal Core Module
• Endocrine Disease Expansion
• Metabolic Disease Expansion
• Immunometabolic Expansion
• Pancreatic Dysfunction Expansion
• Cardiometabolic Risk Expansion
• Mitochondrial Dysfunction Expansion

1. SCOPE & POSITIONING

Etiology / Classification

New-Onset Type 2 Diabetes Postpartum (NT2D-PP) is a chronic metabolic disorder characterized by the development of persistent hyperglycemia after childbirth due to progressive insulin resistance and pancreatic β-cell dysfunction.

The disorder may emerge:

• Following Gestational Diabetes Mellitus (GDM)
• Following Persistent Gestational Diabetes
• In women with pre-existing insulin resistance
• In women with obesity-associated metabolic dysfunction
• Through postpartum metabolic decompensation revealing latent Type 2 Diabetes susceptibility

Unlike Persistent Gestational Diabetes, which represents continuation of pregnancy-associated dysglycemia, New-Onset Type 2 Diabetes Postpartum represents establishment of chronic diabetic pathophysiology.

SCF Classification

SCF Disease Category: Chronic Immunometabolic Failure Syndrome

SCF Functional Class:

Maternal Pancreatic-Endocrine Metabolic Collapse Disorder

SCF Fault Tier Classification

Clinical Significance

New-Onset Type 2 Diabetes Postpartum represents a major long-term maternal health risk.

Potential complications include:

• Diabetic nephropathy
• Diabetic retinopathy
• Diabetic neuropathy
• Cardiovascular disease
• Stroke
• Peripheral vascular disease
• Nonalcoholic fatty liver disease
• Chronic kidney disease
• Future pregnancy complications

SCF Domain Alignment

Primary Domains:

• Endocrine
• Metabolic
• Pancreatic
• Cardiometabolic

Secondary Domains:

• Hepatic
• Vascular
• Renal
• Mitochondrial
• Immune

2. ETIOPATHOGENIC CORE

Primary Cause

New-Onset Type 2 Diabetes Postpartum develops through convergence of:

• Progressive insulin resistance
• β-cell functional exhaustion
• Chronic immunometabolic activation
• Adipose tissue dysfunction
• Mitochondrial bioenergetic impairment
• Endocrine-metabolic maladaptation

Key Drivers

Driver A — Progressive Insulin Resistance

Persistent abnormalities in:

• Skeletal muscle glucose uptake
• Hepatic glucose regulation
• Adipose insulin responsiveness

Result:

• Chronic hyperglycemia

Driver B — β-Cell Failure

Mechanisms include:

• Glucotoxicity
• Lipotoxicity
• Oxidative stress
• Secretory exhaustion

Result:

• Inadequate insulin production

Driver C — Adipose Tissue Inflammation

Features:

• Visceral adiposity
• Macrophage infiltration
• Adipokine dysregulation

Result:

• Amplification of insulin resistance

Driver D — Mitochondrial Dysfunction

Consequences:

• Reduced ATP production
• Metabolic inflexibility
• Oxidative stress escalation

Result:

• Progressive endocrine failure

3. SCF FAULT ARCHITECTURE

4. PATHOGENESIS FLOW (SCF LOGIC)

Postpartum Metabolic Vulnerability

↓

Persistent Insulin Resistance

↓

Adipose Tissue Dysfunction

↓

Chronic Inflammatory Activation

↓

β-Cell Compensation

↓

β-Cell Exhaustion

↓

Reduced Insulin Production

↓

Hyperglycemia

↓

Glucotoxicity

↓

Further β-Cell Damage

↓

Established Type 2 Diabetes

↓

Progressive Organ Injury

↓

Cardiometabolic Disease

5. CLINICAL SPECTRUM

6. SCF TRINITY FRAMEWORK MAPPING

Trinity Axis I — Structural Integrity

Affected Systems:

• Pancreatic islets
• Adipose tissue
• Hepatic metabolic architecture

Primary Failure:

• Endocrine-metabolic organ dysfunction

Trinity Axis II — Energetic Integrity

Affected Systems:

• Mitochondria
• ATP generation systems
• Glucose utilization pathways

Primary Failure:

• Bioenergetic inefficiency

Trinity Axis III — Informational Integrity

Affected Systems:

• Insulin signaling networks
• Glucose sensing systems
• Endocrine-metabolic communication

Primary Failure:

• Metabolic signaling collapse

7. DIABETES EXPANSION MODULE

Clinical Subtype Registry

Type A

Post-Gestational Diabetes Type 2 Diabetes

Characteristics:

• Most common subtype
• Evolves from prior GDM

Type B

Obesity-Associated Postpartum Type 2 Diabetes

Characteristics:

• Severe insulin resistance
• Visceral adiposity dominant

Type C

β-Cell Failure Dominant Type 2 Diabetes

Characteristics:

• Marked insulin secretory deficiency
• Faster progression

Type D

Metabolic Syndrome-Associated Type 2 Diabetes

Characteristics:

• Hypertension
• Dyslipidemia
• Central obesity

Type E

Early Complication Type 2 Diabetes

Characteristics:

• Rapid microvascular injury
• Early organ involvement

8. MULTI-OMICS PATHOGENESIS MAP

9. SCF PCR THERAPEUTIC STRATEGY

PREVENTATIVE

Objectives

Prevent progression from postpartum dysglycemia to established Type 2 Diabetes.

Targets:

• Insulin resistance
• Obesity
• Inflammation
• β-cell stress

CURATIVE

Objectives

Restore glycemic control and preserve pancreatic function.

Targets:

• Hyperglycemia
• Insulin resistance
• β-cell dysfunction
• Metabolic inflammation

Interventions:

• Lifestyle optimization
• Medical nutrition therapy
• Structured exercise
• Glucose-lowering pharmacotherapy when indicated

RESTORATIVE

Objectives

Re-establish long-term metabolic homeostasis.

Targets:

• β-cell preservation
• Mitochondrial recovery
• Insulin signaling restoration
• Cardiometabolic risk reduction

Potential strategies:

• Precision metabolic rehabilitation
• SCF-derived β-cell preservation platforms
• Mitochondrial restorative therapeutics

10. CURRENT STANDARD OF CARE

Diagnostic Evaluation

Glycemic Assessment

• Fasting plasma glucose
• HbA1c
• Oral glucose tolerance test
• Continuous glucose monitoring when appropriate

Cardiometabolic Assessment

• Lipid profile
• Blood pressure
• BMI
• Waist circumference

Complication Screening

• Renal function assessment
• Retinal examination
• Neuropathy evaluation

Treatment

Lifestyle Intervention

• Nutritional therapy
• Weight management
• Physical activity optimization

Pharmacologic Therapy

When clinically indicated:

• Metformin
• GLP-1 receptor agonist therapy (appropriate candidates)
• SGLT2 inhibitor therapy (appropriate candidates)
• Insulin therapy when required

11. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

SCF Target Cluster A

β-Cell Preservation Platform

Targets:

• β-cell survival pathways
• Islet regeneration
• Secretory reserve preservation

SCF Target Cluster B

Insulin Sensitivity Restoration Platform

Targets:

• PI3K/AKT signaling
• GLUT4 translocation
• AMPK activation

SCF Target Cluster C

Immunometabolic Modulation Platform

Targets:

• TNF-α
• IL-6
• NF-κB
• Adipose inflammation

SCF Target Cluster D

Mitochondrial Resilience Platform

Targets:

• ATP generation
• Oxidative stress reduction
• Metabolic flexibility

12. TRANSLATIONAL BLUEPRINT

Diagnostic Biomarkers

Glycemic

• HbA1c
• Fasting glucose
• OGTT metrics

Endocrine

• Insulin
• C-peptide

Inflammatory

• CRP
• IL-6
• TNF-α

Metabolic

• Adiponectin
• Leptin
• Mitochondrial stress biomarkers

Clinical Endpoints

Primary:

• Glycemic normalization

Secondary:

• Preservation of β-cell function
• Reduction in diabetes complications
• Cardiometabolic risk reduction

FDA Translational Pathway

Preclinical

↓

IND

↓

Phase I Safety

↓

Phase II Proof-of-Concept

↓

Phase III Outcomes

↓

NDA/BLA Submission

13. SCF DBI INTERPRETATION

Decentralized Biological Intelligence Failure

Cellular Layer

Insulin-responsive tissues lose metabolic responsiveness.

Tissue Layer

Adipose, hepatic, and pancreatic communication becomes chronically dysregulated.

Organ Layer

Pancreatic islets progressively lose adaptive capacity.

System Layer

Glucose regulation becomes persistently unstable.

Whole-Organism Layer

Maternal metabolic recovery transitions into chronic endocrine disease.

14. SCF LAYMAN’S SUMMARY

New-Onset Type 2 Diabetes Postpartum is a chronic form of diabetes that develops after childbirth when the body can no longer properly regulate blood sugar levels.

According to the SCF model, the disease develops when insulin resistance persists after pregnancy and the pancreas gradually loses its ability to produce enough insulin. This leads to sustained high blood sugar levels and increases the risk of long-term complications affecting the heart, kidneys, nerves, eyes, and blood vessels.

Common symptoms include:

• Increased thirst
• Frequent urination
• Fatigue
• Blurred vision
• Unexplained weight changes
• Increased hunger

Early diagnosis and long-term metabolic management can substantially reduce the risk of chronic complications and improve long-term maternal health outcomes.

SCF-RDOS INDICATION SUMMARY